Cannabis Company Closures and Bankruptcies: Industry Consolidation Trends

Executive Summary

The U.S. cannabis industry has experienced a wave of company closures and bankruptcies since 2022, with dozens of operators shuttering operations amid regulatory challenges, oversupply, and capital market constraints. Atlantic Medicinal Partners became the latest casualty in May 2026, closing its medical cannabis operations while facing $6.11 million in lawsuits. The closure wave reflects structural problems in state-legal cannabis markets: punitive federal tax treatment under 26 U.S.C. § 280E, restricted access to traditional banking, wholesale price compression exceeding 70% in mature markets, and regulatory compliance costs that can consume 15-25% of revenue. Multi-state operators (MSOs) including MedMen, Harborside, and Parallel have filed for bankruptcy protection or undergone distressed restructurings. Smaller single-state operators face even steeper odds, with industry analysts estimating that 30-40% of licensed cannabis businesses operating in 2021 will not survive through 2027. The consolidation reshapes market structure, concentrating market share among well-capitalized survivors while leaving patients with fewer access points and employees without jobs in an industry that employed over 428,000 workers at its 2023 peak.

Why This Matters

Cannabis company failures affect patients, employees, investors, and the credibility of state legalization programs nationwide. When a licensed dispensary or cultivation facility closes, medical cannabis patients lose access points—particularly critical in rural areas where the nearest alternative may be 50+ miles away. Atlantic Medicinal Partners served medical patients in Delaware, a state with only 13 active dispensary licenses as of May 2026. Each closure reduces patient choice and can force vulnerable populations back to unregulated markets. The employment impact is substantial. The cannabis industry supported approximately 428,000 full-time equivalent jobs across the United States in 2023, according to industry workforce data. Mass layoffs at Curaleaf, Trulieve, and Verano in 2024-2025 eliminated an estimated 8,000-12,000 positions as companies restructured. Unlike traditional industries, displaced cannabis workers face barriers to unemployment benefits in some states due to federal illegality, and their experience may not transfer to federally-compliant sectors. Investors—ranging from institutional funds to individual shareholders—have lost billions. The AdvisorShares Pure US Cannabis ETF (MSOS) declined 78% from its February 2021 peak through May 2026, erasing over $3 billion in market capitalization. Retail investors who purchased cannabis stocks during the 2020-2021 hype cycle face near-total losses in many cases, with MedMen shares trading below $0.01 before delisting. State governments also feel the impact through reduced tax revenue. California cannabis tax collections fell 18% year-over-year in fiscal 2024-2025, partly due to operator failures and market contraction. When licensed operators fail, illicit market activity often fills the void, undermining the core policy rationale for legalization.

Background and History: From Green Rush to Bankruptcy Wave

The cannabis industry's financial crisis emerged from the collision of explosive growth expectations with harsh economic and regulatory realities.

2018-2019: The Green Rush and Capital Influx

The modern cannabis bankruptcy wave has roots in the 2018-2019 capital boom. Following Canada's federal legalization in October 2018 and the 2018 U.S. Farm Bill's hemp provisions, cannabis companies attracted unprecedented investment. U.S. cannabis companies raised $13.7 billion in capital during 2018-2019, according to Viridian Capital Advisors tracking data. Multi-state operators pursued aggressive expansion strategies, acquiring licenses across multiple states and building cultivation capacity to capture anticipated demand. MedMen exemplified the era's exuberance. The California-based retailer operated 33 stores across 12 states by mid-2019, raised over $1 billion, and achieved a $3 billion valuation. The company spent lavishly on executive compensation, real estate, and marketing, anticipating that federal legalization would arrive within 2-3 years. MedMen's founders awarded themselves $24 million in compensation in 2018 alone, according to securities filings.

2020-2021: Pandemic Boom Masks Structural Problems

The COVID-19 pandemic temporarily obscured underlying problems. U.S. cannabis sales surged 46% in 2020 to reach $17.5 billion, as states designated dispensaries as essential businesses and consumers stockpiled products during lockdowns. Reddit-fueled retail investor enthusiasm drove cannabis stocks to record highs in February 2021, with the MSOS ETF reaching $60 per share. However, structural problems were already emerging. Wholesale cannabis prices began declining in mature markets as cultivation capacity outpaced demand. Oregon wholesale flower prices fell from $1,500 per pound in 2018 to under $500 per pound by late 2020. California, Michigan, and Colorado experienced similar compression. Operators who had built capacity assuming sustained price levels faced margin erosion.

2022: The Correction Begins

The bankruptcy wave began in earnest during 2022. MedMen filed for bankruptcy protection in June 2022, listing $411 million in assets against $577 million in liabilities. The company's collapse stemmed from operational losses exceeding $100 million annually, lease obligations it could not sustain, and vendor debts it could not pay under 280E tax constraints. Harborside Inc., one of California's oldest dispensary operators, filed for bankruptcy in November 2022 after accumulating $22 million in debt. The company cited 280E tax burdens and California's high regulatory costs as primary factors. Harborside had operated since 2006 as a collective, converting to a for-profit corporation in 2018 to access capital markets—a decision that ultimately proved fatal as it triggered full 280E exposure. Parallel, a Florida-focused MSO, entered bankruptcy restructuring in December 2022 with $439 million in debt. The company had expanded aggressively into Massachusetts, Nevada, and Texas, but failed to generate sufficient cash flow to service high-interest debt incurred during the 2019-2020 expansion.

2023-2024: Cascading Failures and Fire Sales

The crisis accelerated through 2023 and 2024. At least 47 licensed cannabis companies filed for bankruptcy protection or underwent distressed asset sales during this period, according to bankruptcy court tracking. The failures spanned all market segments: cultivators, processors, retailers, and vertically integrated operators. Cultivation facilities faced particularly acute pressure. Wholesale cannabis biomass prices in California fell to $200-300 per pound by mid-2023, below the cost of production for most indoor cultivators. Dozens of cultivation licenses went dormant or were surrendered. In Oklahoma, which had issued over 9,000 cultivation licenses by 2022, an estimated 40% ceased active operations by 2024. Retailers faced a different challenge: market saturation. Michigan issued over 1,500 retail licenses by 2023, creating intense competition that drove margins to unsustainable levels. Smaller operators could not compete with MSO pricing power and marketing budgets. According to Michigan Cannabis Regulatory Agency data, approximately 200 retail licenses were revoked or voluntarily surrendered during 2023-2024 due to non-operation or financial failure.

2025-2026: Continued Consolidation

The consolidation continued through 2025 and into 2026. Atlantic Medicinal Partners' May 2026 closure amid $6.11 million in lawsuits represents the ongoing attrition among smaller operators. The Delaware-based medical cannabis company could not sustain operations while facing vendor lawsuits, landlord disputes, and accumulated tax obligations. The bankruptcy wave has fundamentally reshaped market structure. The top four MSOs—Curaleaf, Trulieve, Green Thumb Industries, and Verano—controlled approximately 35% of U.S. legal cannabis sales by early 2026, up from 22% in 2021. Market share concentration continues to increase as distressed assets are acquired by better-capitalized competitors at steep discounts.

Key Players in the Bankruptcy Wave

MedMen Enterprises

MedMen's 2022 bankruptcy marked the most prominent failure of the Green Rush era. Founded in 2010 by Adam Bierman and Andrew Modlin, MedMen positioned itself as the "Apple Store of weed," operating high-end retail stores with premium design. The company's downfall stemmed from executive excess, operational losses, and debt service obligations it could not meet. After bankruptcy, MedMen's assets were sold piecemeal to competitors, with Ascend Wellness acquiring its Illinois operations and other MSOs purchasing individual store licenses.

Harborside Inc.

Harborside operated one of California's first medical cannabis dispensaries, opening in Oakland in 2006. The company's bankruptcy in November 2022 illustrated how even established operators with brand recognition could not survive California's tax and regulatory environment. Harborside emerged from bankruptcy in 2023 under new ownership, but with a significantly reduced footprint—operating only four dispensaries compared to 13 pre-bankruptcy.

Parallel

Parallel's bankruptcy restructuring involved $439 million in debt, primarily high-interest notes issued during its 2019-2020 expansion. The company's secured lenders took control through the bankruptcy process, wiping out equity holders. Parallel emerged in 2023 as a private company focused solely on Florida, having divested its Massachusetts, Nevada, and Texas operations.

Atlantic Medicinal Partners

Atlantic Medicinal Partners operated medical cannabis dispensaries in Delaware, one of the smallest state markets. The company's May 2026 closure amid $6.11 million in lawsuits reflects the challenges facing operators in limited-license states with small patient populations. Delaware's medical cannabis program served approximately 15,000 registered patients as of 2025—insufficient to support 13 competing dispensary operators. Atlantic Medicinal Partners faced vendor lawsuits, landlord disputes over unpaid rent, and tax obligations that accumulated under 280E constraints.

Smaller Operators and Cultivation Facilities

Beyond high-profile MSO failures, hundreds of smaller operators have quietly closed. Single-state operators, particularly cultivation-only licensees, have experienced failure rates exceeding 40% in oversupplied markets. These closures rarely generate headlines but represent the majority of industry attrition. In Oklahoma, California, Oregon, and Michigan—states with unlimited or high license caps—cultivation license surrenders and revocations numbered in the hundreds during 2023-2025.

Legal and Regulatory Framework Driving Failures

Federal prohibition creates unique financial burdens that make cannabis businesses structurally unprofitable compared to legal industries.

26 U.S.C. § 280E: The Tax Death Spiral

Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Cannabis companies can deduct cost of goods sold (COGS) but cannot deduct rent, salaries, marketing, insurance, or other operating expenses. This results in effective tax rates of 40-70% of gross profit, compared to 15-25% for comparable legal businesses. A dispensary with $5 million in revenue, $2 million in COGS, and $2.5 million in operating expenses would show $500,000 in pre-tax profit under normal accounting. Under 280E, the company owes federal tax on $3 million ($5 million revenue minus $2 million COGS), resulting in a tax bill exceeding $1 million—double its actual profit. This tax treatment alone has driven dozens of operators into insolvency.

Banking Access and Capital Constraints

Federal prohibition under 21 U.S.C. § 812 (Controlled Substances Act) makes banks reluctant to serve cannabis companies due to money laundering concerns under 18 U.S.C. § 1956. While the Financial Crimes Enforcement Network (FinCEN) issued guidance in 2014 allowing banks to serve cannabis businesses with enhanced due diligence, most major banks decline cannabis accounts. Cannabis companies pay 3-5% of revenue for cash management services that legal businesses receive free. They cannot access traditional credit lines, forcing reliance on high-interest private debt. During the 2022-2024 bankruptcy wave, many failed companies carried debt at 12-18% interest rates—unsustainable given industry margins.

State Regulatory Costs

State compliance costs add additional burden. California cannabis operators face effective tax rates of 30-35% when combining state excise tax (15%), cultivation tax (previously $10.08 per ounce of flower), and local taxes that can reach 10-15%. Regulatory compliance costs—including seed-to-sale tracking, testing, packaging, and labeling requirements—add 15-25% to operational costs.

Bankruptcy Code Limitations

Cannabis companies face unique challenges in bankruptcy. Under 11 U.S.C. § 362, the automatic stay that protects bankrupt companies from creditors can be challenged on grounds that the debtor's business violates federal law. Some bankruptcy courts have dismissed cannabis cases or required companies to cease operations during bankruptcy proceedings. This uncertainty makes bankruptcy less effective as a restructuring tool compared to legal industries.

State-by-State Market Conditions

Operator failure rates vary dramatically by state based on license structure, market maturity, and regulatory costs.

California

California has experienced the highest absolute number of cannabis business failures. The state's unlimited licensing, high taxes, and burdensome regulations have created an environment where an estimated 35-40% of licensed operators ceased operations between 2021 and 2025. Wholesale flower prices fell from $1,200 per pound in 2020 to $300-400 per pound by 2024. Los Angeles alone issued over 1,000 retail licenses, creating unsustainable competition. The state's cultivation tax, eliminated in July 2022, had already driven dozens of cultivators out of business.

Michigan

Michigan issued over 1,500 retail licenses and 1,000 cultivation licenses by 2023, creating severe oversupply. Wholesale prices fell 60% between 2021 and 2024. Approximately 200 licenses were surrendered or revoked during 2023-2024. The state's relatively low barriers to entry attracted more operators than the market could sustain, particularly in metropolitan Detroit where over 200 dispensaries competed within a 30-mile radius.

Oklahoma

Oklahoma's medical cannabis program issued over 9,000 cultivation licenses and 2,000 dispensary licenses between 2018 and 2022—far exceeding the state's patient population of approximately 400,000. By 2024, an estimated 40% of cultivation licenses were inactive or surrendered. Wholesale prices collapsed to $150-250 per pound. The state implemented emergency rules in 2022 requiring proof of Oklahoma residency for license holders, forcing out-of-state investors to divest, which accelerated closures.

Oregon

Oregon was an early mover in legalization but suffered from oversupply. The state issued unlimited cultivation licenses, resulting in over 2,000 active grows by 2020. Wholesale prices fell to $300-400 per pound by 2021, well below production costs for most operators. The Oregon Liquor and Cannabis Commission reported that approximately 30% of cultivation licenses became inactive between 2021 and 2024. The state imposed a moratorium on new cultivation licenses in 2023 to address oversupply.

Florida

Florida's limited-license medical market has seen fewer outright failures but significant consolidation. Trulieve controls approximately 50% of Florida's medical cannabis market as of 2026, having acquired several struggling competitors including Harvest Health & Recreation in 2021. The state's vertical integration requirement and high license costs (over $60,000 annually) create barriers that protect existing operators but also make failure more catastrophic when it occurs.

Delaware

Delaware's small medical market with only 13 dispensary licenses and approximately 15,000 patients created an environment where Atlantic Medicinal Partners could not generate sufficient revenue to sustain operations while facing $6.11 million in legal judgments. The state's limited patient population meant each dispensary served an average of only 1,150 patients—insufficient to support full-scale operations profitably under 280E tax treatment.

Illinois

Illinois' limited-license structure has resulted in fewer failures but significant distress. The state's high license fees, strict regulatory requirements, and social equity program complications have created financial pressure even in a protected market. Several social equity licensees have sold to MSOs after being unable to secure sufficient capital to build out operations. The state issued only 185 adult-use dispensary licenses initially, but many remain unopened due to capital constraints.

Market and Business Implications

The bankruptcy wave is reshaping cannabis industry structure, with market share concentrating among well-capitalized MSOs while smaller operators exit.

Consolidation and Market Concentration

The top four MSOs increased their combined market share from 22% in 2021 to approximately 35% by early 2026. Curaleaf, Trulieve, Green Thumb Industries, and Verano have acquired distressed assets at steep discounts, expanding their footprints while competitors contracted. Curaleaf acquired Select's Arizona operations from bankrupt Cura Partners in 2023. Trulieve purchased Harvest Health & Recreation's assets for $2.1 billion in 2021, then acquired additional distressed Florida operators in 2023-2024. This consolidation creates economies of scale that smaller operators cannot match. Large MSOs negotiate better wholesale pricing, spread fixed costs across more locations, and access cheaper capital. However, concentration also raises antitrust concerns and reduces consumer choice.

Wholesale Price Compression

Wholesale cannabis prices have fallen 60-75% in mature markets since 2020. California wholesale flower averaged $300-400 per pound in 2024, down from $1,200 in 2020. Michigan, Oregon, and Oklahoma experienced similar declines. This compression makes cultivation unprofitable for most operators, particularly indoor grows with high energy costs. Price compression stems from oversupply, improving cultivation efficiency, and market maturation. Indoor cultivation costs typically range from $400-600 per pound when including labor, energy, rent, and compliance costs—meaning most indoor operators lose money at current wholesale prices. Only the most efficient cultivators, typically large-scale greenhouse or outdoor operations, remain profitable.

Capital Market Freeze

Cannabis capital markets effectively froze during 2022-2024. U.S. cannabis companies raised only $1.8 billion in 2023, down 87% from the $13.7 billion raised in 2018-2019. Equity markets remained largely closed, with most cannabis stocks trading below $1 per share and unable to access institutional capital. Debt markets offered only high-interest private loans at 12-18% rates. This capital drought prevents operators from investing in efficiency improvements, expanding into new markets, or weathering temporary losses. Companies that might survive with access to working capital instead face closure due to inability to bridge short-term cash flow gaps.

Employment and Labor Market Impact

The cannabis industry employed approximately 428,000 full-time equivalent workers in 2023, but employment contracted during 2024-2025. Major MSOs announced layoffs totaling 8,000-12,000 positions during this period. Curaleaf reduced headcount by 15% in 2024. Trulieve eliminated approximately 1,000 positions. Smaller operator closures added thousands more job losses. Cannabis workers face unique challenges. Many cannot access unemployment benefits due to federal illegality. Their experience may not transfer to other industries due to stigma and federal employment restrictions. Cultivation and processing workers, in particular, struggle to find comparable employment when facilities close.

Impact on Ancillary Businesses

Cannabis operator failures cascade to ancillary businesses. Equipment suppliers, testing laboratories, packaging companies, and software vendors face payment defaults and lost customers. Several cannabis-focused testing labs closed during 2023-2024 as cultivator clients went bankrupt. Equipment leasing companies repossessed extraction equipment, grow lights, and processing machinery from failed operators, flooding the secondary market and depressing values.

What Experts Say

Industry analysts, attorneys, and operators identify federal prohibition, oversupply, and capital constraints as the primary drivers of cannabis business failures. Cannabis industry analyst Matt Karnes of GreenWave Advisors has tracked the bankruptcy wave since 2022. According to his research, the combination of 280E tax treatment and restricted banking access creates a structural disadvantage that makes cannabis businesses 40-60% less profitable than comparable legal businesses. Karnes noted in a 2025 industry presentation that even well-managed cannabis companies struggle to achieve net margins above 10%, while 280E alone can reduce margins by 15-25 percentage points. Kris Krane, president of 4Front Ventures and a longtime cannabis industry executive, has spoken publicly about the challenges facing operators. In a 2024 industry conference presentation, Krane described how 280E forces companies to choose between paying taxes and paying vendors, creating a death spiral where unpaid vendors sue, legal judgments accumulate, and companies cannot restructure effectively due to bankruptcy code limitations on cannabis businesses. Bankruptcy attorney Garrett Sutton, who has represented multiple cannabis companies in Chapter 11 proceedings, explained in a 2025 legal journal article that cannabis bankruptcies face unique challenges. Courts in some jurisdictions have dismissed cases on grounds that the debtor's ongoing business violates federal law under 21 U.S.C. § 812. This uncertainty makes bankruptcy less effective as a restructuring tool, forcing more companies into liquidation rather than reorganization. Oregon cannabis cultivator and industry advocate Adam Smith, who chairs the Oregon Cannabis Association, has testified before state legislators about market conditions. According to his 2024 testimony, wholesale prices in Oregon fell below the cost of production for approximately 70% of licensed cultivators, forcing hundreds out of business. Smith advocated for license caps and supply controls to stabilize markets, but noted that such measures come too late for operators who have already invested millions in facilities and licenses. Financial analyst Vivien Azer of Cowen & Company, who covers cannabis stocks, downgraded most MSO ratings during 2023-2024 based on deteriorating fundamentals. In research notes, Azer identified margin compression, capital market access, and regulatory uncertainty as key headwinds. Her analysis showed that publicly traded MSOs traded at an average of 4-6 times EBITDA in 2024, compared to 12-15 times for comparable consumer packaged goods companies, reflecting investor skepticism about long-term viability under current federal prohibition.

What's Next: Scenarios and Outlook

The cannabis industry consolidation will continue through 2027-2028, with outcomes depending heavily on federal policy decisions.

Near-Term Outlook (2026-2027)

Industry analysts project continued operator attrition through 2027. An estimated 30-40% of cannabis businesses operating in 2021 will not survive through 2027, based on current failure rates and market conditions. Smaller single-state operators face the highest risk, particularly cultivation-only licensees in oversupplied markets. The Drug Enforcement Administration's proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act could provide relief if finalized. The DEA published a Notice of Proposed Rulemaking in May 2024, with a final rule expected in late 2026 or early 2027. Rescheduling to Schedule III would eliminate 280E tax treatment, potentially improving cannabis company margins by 15-25 percentage points. However, rescheduling would not resolve banking access issues or state-level regulatory burdens.

Federal Legislation Scenarios

Congressional action remains uncertain. The SAFER Banking Act, which would provide cannabis businesses access to traditional banking, has passed the House multiple times but stalled in the Senate. If enacted, SAFER Banking would reduce cash management costs and improve access to credit, potentially preventing some operator failures. Comprehensive federal legalization or descheduling would fundamentally alter industry dynamics. However, most industry observers do not expect full federal legalization before 2028-2030 at the earliest, based on current political dynamics and congressional priorities.

Market Stabilization Factors

Some factors may stabilize markets and reduce failure rates. Several states have implemented license caps or moratoriums on new cultivation licenses to address oversupply. Oregon, California, and Washington have all taken steps to limit new licenses. These supply controls could allow wholesale prices to stabilize or recover modestly. Demand growth continues in newer markets. States that legalized adult-use cannabis in 2022-2024, including Maryland, Missouri, and Ohio, are experiencing strong sales growth that may absorb some excess supply. However, these markets will likely mature and face their own oversupply challenges within 3-5 years.

Consolidation Endgame

Industry structure will likely stabilize with 8-12 dominant MSOs controlling 50-60% of the national market, alongside regional operators and a long tail of smaller businesses serving niche markets. This structure mirrors alcohol distribution, where major companies coexist with craft producers. The survivors will be operators with strong balance sheets, efficient operations, and diversified geographic footprints. Curaleaf, Trulieve, Green Thumb Industries, and Verano are positioned to emerge as national leaders, while regional operators like Ascend Wellness, Ayr Wellness, and Cresco Labs may dominate specific geographic markets.

Further Reading and Primary Sources

• 26 U.S.C. § 280E (Internal Revenue Code Section 280E) - https://www.law.cornell.edu/uscode/text/26/280E
• 21 U.S.C. § 812 (Controlled Substances Act scheduling provisions) - https://www.law.cornell.edu/uscode/text/21/812
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 2024) - https://www.federalregister.gov/
• FinCEN Guidance on Marijuana-Related Businesses (FIN-2014-G001) - https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• MedMen Enterprises bankruptcy filings (Case No. 22-10327, U.S. Bankruptcy Court, Central District of California) - https://www.pacermonitor.com/
• Harborside Inc. bankruptcy filings (Case No. 22-51315, U.S. Bankruptcy Court, Northern District of California) - https://www.pacermonitor.com/
• Viridian Capital Advisors Cannabis Deal Tracker - https://www.viridianca.com/
• Michigan Cannabis Regulatory Agency licensing data - https://www.michigan.gov/cra
• California Department of Cannabis Control licensing statistics - https://cannabis.ca.gov/
• Oregon Liquor and Cannabis Commission market data - https://www.oregon.gov/olcc/
• Cowen & Company cannabis industry research reports (subscription required) - https://www.cowen.com/
• GreenWave Advisors industry analysis - https://www.greenwaveadvisors.com/
• SAFER Banking Act legislative text (H.R. 2891, 118th Congress) - https://www.congress.gov/bill/118th-congress/house-bill/2891
• AdvisorShares Pure US Cannabis ETF (MSOS) performance data - https://www.advisorshares.com/etfs/msos/